Adipogen/Pifithrin-α · hydrobromide/AG-CR1-0004-M005/5 mg-蚂蚁淘商城

新闻动态

Adipogen/Pifithrin-α · hydrobromide/AG-CR1-0004-M005/5 mg

2024-05-06

More Information Product Details Synonyms Product Type Properties Formula MW CAS Purity Chemicals Appearance Solubility Identity InChi Key Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

1-(4-Methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone . HBr, Pfithrin alpha

Chemical

C₁₆H₁₈N₂OS . HBr

286.4 . 80.9

63208-82-2

≥98% (NMR)

White to off-white solid.

Soluble in DMSO or 100% ethanol.

Determined by ¹H-NMR.

HAGVCKULCLQGRF-UHFFFAOYSA-N

AMBIENT

+4°C

-20°C

Keep under inert gas.Protect from light.

Stable for at least 2 years after receipt when stored at -20°C.

Download PDF

p53 inhibitor [1, 2].
Reversibly blocks p53-dependent transcriptional activation [2].
Tool to combat side effects of cancer therapy [3].
Apoptosis inhibitor [1, 2, 4].

Product References

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy: P.G. Komarov, et al.; Science 285, 1733 (1999)

Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation: P.J. Murphy, et al.; J. Biol. Chem. 279, 30195 (2004)

Cancer research. A new way to combat therapy side effects: D. Ferber; Science 285, 1651 (1999)

Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio: D. Javelaud & F. Besancon; J. Biol. Chem. 277, 37949 (2002)

本文链接： https://www.ebiomall.cn/b209-komabiotech/info-1554447405.html

免责声明本文仅代表作者个人观点，与本网无关。其创作性以及文中陈述文字和内容未经本站证实，对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺，请读者仅作参考，并请自行核实相关内容。

没有了

Noanix将参展上海国际机床展览会月韩国机械展

2021-05-05

助行康复机器人前景广阔

2021-05-13

中国医疗机器人行业图谱：2家上市，12家获得融资，近三分之一的团队来自哈工大

2021-05-22

代理销售BELLIN SPA泵-化工仪器网

2021-05-31

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment | Journal of Experimental & Clinical Cancer Research | Full Text